Private Equity partner Roger Cohen and associates Dustin Schaefer and Anne Brendel share analysis and key focus areas on prescriptions for a new class of drugs to treat obesity that surged exponentially in 2023. Originally approved for treatment of Type 2 diabetes, glucagon-like peptide-1 receptor agonist drugs, or GLP-1s, such as Wegovy, Zepbound, Ozempic and Mounjaro have been a popular choice for obesity treatment and general weight loss despite the drugs' significant price tags and limited insurance coverage. Some estimates project that sales of GLP-1s will exceed $100 billion by 2030. Weight loss medication prescribers, including telehealth platforms, and pharmacies should stay abreast of new and ongoing regulatory scrutiny and the changing regulatory and payor landscape related to weight loss drug prescriptions. More in Law360.